Fmr LLC Cuts Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Fmr LLC cut its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 3.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,026,956 shares of the company’s stock after selling 1,230,644 shares during the period. Fmr LLC owned 14.32% of Allogene Therapeutics worth $84,075,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Nisa Investment Advisors LLC lifted its holdings in shares of Allogene Therapeutics by 429.6% in the second quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock worth $25,000 after buying an additional 8,734 shares in the last quarter. Federated Hermes Inc. purchased a new stake in Allogene Therapeutics in the 2nd quarter worth $29,000. Phoenix Wealth Advisors purchased a new stake in Allogene Therapeutics in the 2nd quarter worth $30,000. Private Advisor Group LLC bought a new position in shares of Allogene Therapeutics during the 3rd quarter valued at about $34,000. Finally, Algert Global LLC purchased a new position in shares of Allogene Therapeutics during the second quarter valued at about $35,000. 83.63% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Citigroup boosted their target price on Allogene Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Canaccord Genuity Group lowered their target price on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Allogene Therapeutics in a report on Friday, November 8th. Oppenheimer began coverage on shares of Allogene Therapeutics in a research note on Thursday, August 8th. They set an “outperform” rating and a $11.00 price target on the stock. Finally, Truist Financial reissued a “buy” rating and issued a $14.00 price objective (down from $17.00) on shares of Allogene Therapeutics in a research note on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.73.

Allogene Therapeutics Stock Down 5.3 %

Shares of NASDAQ ALLO opened at $2.14 on Friday. Allogene Therapeutics, Inc. has a twelve month low of $1.99 and a twelve month high of $5.78. The firm has a market cap of $448.69 million, a PE ratio of -1.36 and a beta of 0.83. The business has a fifty day simple moving average of $2.63 and a two-hundred day simple moving average of $2.60.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).